Claes Glassell Appointed Cambrex Corporation President & Chief Operating Officer
Cambrex Corporation (NYSE: CBM), announced today the appointment of Claes Glassell as President and Chief Operating Officer. Mr. Glassell was also elected to the Cambrex Corporation Board of Directors.
Mr. Glassell joined Cambrex in 1994 through the Company’s acquisition of Nobel Pharma where he had been President since 1989. While at Cambrex, Mr. Glassell has held the positions of President - Pharmaceuticals Group and most recently Executive Vice President & Chief Operating Officer with responsibility for Cambrex’s Biosciences, Pharmaceutical and Fine Chemicals businesses. He has a Masters in Chemical Engineering from Chalmers University of Technology in Gothenberg, Sweden and is a graduate of the Advanced Management Program at Harvard University.
James A. Mack, Cambrex Chairman and Chief Executive Officer, said, “Claes has done an excellent job in building our pharmaceutical and biotechnology businesses. Cambrex’s focus continues to be on supplying proprietary products and services to the life sciences industry in support of drug discovery, development and commercial scale manufacturing. I look forward to working with Claes to implement our strategic plan and accelerate our growth.”
Cambrex Corporation primarily provides products and services to the life sciences industries.
Topics
Organizations
These products might interest you

Good Weighing Practice by Mettler-Toledo
Your Concrete Weighing Quality Assurance Plan
GWP Verification service

Milli-Q® Services / MyMilli-Q™ by Merck
Services & Support for Water Purification Systems
Quality Care, Delivered. In Person & Online

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
SOLVAY AND K+S SIGN AGREEMENT TO SET UP ESCO, THEIR SALT JOINT VENTURE
Oxea Announces Price Increase for 2 Ethylhexanoic Acid
New testing of model improves confidence in the performance of ITER
New and improved right to the last drop - Trapping enzymes in silica beads

Hanna Instruments GmbH - Graz, Austria
BASF strengthens position in Chinese automotive industry - Closer to the automotive customer with three sites in Asia

Cleanser, S.L. - Alcalá de Guadaíra, Spain
LANXESS to become climate neutral by 2040 - Research focusing on climate neutral process and technology innovations
Arkema brings new resins reactor online in Brazil
